On the stock market since 2000, it operates in the world of health and science. It has 74 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 87% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $142.7M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 72% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 49% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 113% a year on average.
There is $145.6M in the vault; even if every debt were paid off, $142.7M would remain.
This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, CGEN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CGEN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.